David Weber

David Weber, PhD, is the President and CEO of Mosanna Therapeutics, a Redwood City biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea that aims to restore the body's natural airway reflex during sleep. A biotech operator with more than 30 years in drug development, capital formation, and corporate strategy, he previously led Otonomy through its IPO and multiple clinical programs, and served as CEO of MacuSight and Oculex Pharmaceuticals. He joined Mosanna in June 2025 as the company launched with an $80 million Series A.